<DOC>
	<DOCNO>NCT00524875</DOCNO>
	<brief_summary>The purpose study determine whether bevacizumab 1-2 week vitrectomy effective lowering rate early post-vitrectomy vitreous hemorrhage diabetic patient .</brief_summary>
	<brief_title>Effect Intravitreal Bevacizumab Early Post-Vitrectomy Hemorrhage Diabetic Patients</brief_title>
	<detailed_description>Diabetes lead cause blindness age range 20-64 year . Pars plana vitrectomy may indicate management advanced proliferative diabetic retinopathy . Early post-vitrectomy hemorrhage diabetic patient relatively common ; occur 29 % -75 % patient first month surgery . This may cause delayed visual rehabilitation detection surgical complication retinal break detachment . Preliminary report case series report Spaide RF , et al show beneficial effect bevacizumab proliferative diabetic retinopathy complicate vitreous hemorrhage .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>All eye candidate par plana vitrectomy complication diabetic retinopathy nonclearing vitreous hemorrhage , tractional retinal detachment threaten macula , active progressive PDR One eye patient Best correct visual acuity well 20/50 Pregnancy Use internal tamponade silicone oil surgery Concurrent ophthalmic surgery cataract extraction</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Proliferative diabetic retinopathy</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Early post-vitrectomy vitreous hemorrhage</keyword>
</DOC>